Regado gains $23M in financing

Regado Biosciences has landed $23 million in Series C financing. New investor Caxton Advantage Life Sciences Fund, Domain Associates and Quaker BioVentures led the round. The company will use the funding to advance its lead drug, REG1. "We are excited about the prospects for Regado...REG1 has the potential to address some key issues with today's anticoagulants used in antithrombotic markets such as CABG, PCI, and ACS," said Eric Roberts, Managing Director of Caxton Advantage.

- read the company's release for more

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.